Business Context and Reporting Period
This Form 8-K filing by Aileron Therapeutics, Inc. (trading symbol: ALRN) reports a material definitive agreement entered into on June 4, 2020. The company, an emerging growth corporation incorporated in Delaware, is conducting an underwritten public offering of its common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 9,090,910 shares of common stock.
- Public Offering Price: $1.10 per share.
- Underwriter Purchase Price: $1.023 per share.
- Underwriter: William Blair & Company, L.L.C.
- Estimated Net Proceeds: Approximately $9.1 million from the base offering.
- Over-Allotment Option: The underwriter has a 30-day option to purchase up to 1,363,636 additional shares. If fully exercised, total net proceeds are estimated at approximately $10.5 million.
- Expected Closing Date: On or about June 8, 2020.
Material Changes and Other Events
On June 3, 2020, the company terminated its at-the-market (ATM) offering program under the Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. This termination coincides with the launch of the current underwritten public offering.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding the anticipated closing of the offering and the company's future operations. Key risks identified include:
- Sufficiency of cash resources to fund continuing operations and clinical trials.
- Uncertainty regarding preclinical and clinical trial results and their indication of future outcomes.
- Timeliness of regulatory approvals from the FDA or equivalent agencies.
- Potential impact of the coronavirus pandemic on clinical development, supply, and operations.
The company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting all offering expenses.
- Confirm whether the underwriter exercises the 30-day option to purchase the additional 1,363,636 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Assess the company's updated cash runway in light of the $9.1 million to $10.5 million in new capital.